This morning, hoping to call into question its would-be acquirer, Valeant, Allergan issued a press release quoting the global head of M&A at Morgan Stanley, a blogging Australian hedge fund manager, and me. It was not the beginning of a joke where we all walk into a bar. Tomorrow, Valeant is hosting a conference call to try to rebut what it says are misleading questions about its business model made by Allergan and others.